Abstract: The present invention relates to pancreatic cancer, and more particularly to the survival prognosis of a patient suffering from pancreatic cancer. The invention also aims to determine the suitability of said patient to receive a treatment for pancreatic cancer, in particular a treatment with gemcitabine. The invention also concerns a method for monitoring the effectiveness of a treatment for pancreatic cancer, and advantageously a treatment with gemcitabine, by implementing the method.
Abstract: An in vitro method for determining the prognosis of pancreatic cancer in a patient includes the following steps: a) measuring the expression level of at least one gene chosen from the group consisting of: ACOX-1, TNFRSF10B, LYN, HIF1A, UBE2H, PARP2, ABCC1, ABCC3, IGJ and RPS23 or homologous genes, in a blood sample of the patient, b) predicting the outcome of the pancreatic cancer in the patient. a kit specifically designed to carry out such a method is also described.
Type:
Application
Filed:
October 3, 2014
Publication date:
August 25, 2016
Applicants:
AB Science, ACOBIOM
Inventors:
David PIQUEMAL, Alain MOUSSY, Jean-Pierre KINET
Abstract: The present invention relates to a method of prognostic of the survival of human subject suffering from chronic myelomonocytic leukemia (CMML) based on the differential expression of six genes in a test sample of PBMC cells obtained from said human subject and in a control sample of normal cells, wherein said expression level indicates if the human subject from which the test sample has been obtained will have long-term or short-term survival.
Type:
Application
Filed:
February 18, 2013
Publication date:
January 21, 2016
Applicants:
Centre Hospitalier Universitaire Nîmes, ACOBIOM
Inventors:
Davidè PIQUEMAL, Eric JOURDAN, Thérèse COMMES, Elias BOU SAMRA